Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 2449 • ACR Convergence 2024
Acid Reflux Triggers Type I Interferon and Persistent Epithelial-mesenchymal Transition in Esophageal Epithelial Cells. a Novel Microenvironment Contribution to the Pathogenesis of Systemic Sclerosis
Safoura Zahed Mohajerani¹, john ladbury¹, Rebecca Ross² and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Gastroesophageal reflux disease (GERD) is a very common manifestation of scleroderma (SSc), affecting as high as 90% of patients, second only to Raynaud’s phenomenon.…
Abstract Number: 1562 • ACR Convergence 2024
Autoantibody Associations with Disease Manifestations in Patients with Early Diffuse Cutaneous Systemic Sclerosis: The Prospective Registry of Early Systemic Sclerosis
Aradhna Agarwal¹, Dahlia Hassan², Suiyuan Huang³, Flavia Castelino⁴, Shervin Assassi⁵, Robyn Domsic⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Monique Hinchcliff¹⁰, Ami Shah¹¹, Victoria Shanmugam¹², Virginia Steen¹³, Dinesh Khanna³ and Elana Bernstein¹⁴, ¹Columbia University, New York, NY, ²Hospital for Special Surgery, New York, NY, ³University of Michigan, Ann Arbor, MI, ⁴Massachusetts General Hospital, Boston, MA, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Division of Rheumatology, Weill Cornell Medical College, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Yale School of Medicine, Westport, CT, ¹¹Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ¹²NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹³Georgetown University School of Medicine, Washington, DC, ¹⁴Columbia University Irving Medical Center, New York, NY
Background/Purpose: Several autoantibodies have been linked to various disease manifestations of systemic sclerosis (SSc). Anti-RNA polymerase 3 (ARA) and anti-topoisomerase-I (ATA) are both associated with…
Abstract Number: 2452 • ACR Convergence 2024
Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study
Riccardo Bixio¹, Maria Giovanna Lommano², Seda Colak³, Sonia farah⁴, Francesca Pistillo⁵, Richard Wakefield⁶, Fausto Salaffi⁴, Stefano Di Donato⁷, Ombretta Viapiana⁵, Rossella De Angelis⁸, Maurizio Rossini⁵, Edoardo Cipolletta⁹, Emilio Filippucci¹⁰, Luca Idolazzi⁵, Francesco Del Galdo¹¹ and Andrea Di Matteo¹², ¹University of Verona, Verona, Verona, Italy, ²Università Politecnica delle Marche, Jesi, Italy, ³Gulhane Training and Research Hospital, Ankara, Turkey, ⁴Polytechnic University of Marche, Jesi (AN), Italy, ⁵Rheumatology Unit, University of Verona, Verona, Italy, ⁶NIHR Leeds Biomedical Research Centre, Leeds, UK., Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ⁸Polytechnic University of Marche, Ancona, Italy, Ancona, Italy, ⁹Polytechnic University of Marche, Ancona, Italy, ¹⁰Rheumatology Unit, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Jesi, Ancona, Italy, Jesi, Italy, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Faculty of Medicine and Health, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Patients with systemic sclerosis (SSc) are at an increased risk of sarcopenia and muscle involvement. This study aims to describe the ultrasound findings of…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…
Abstract Number: 2455 • ACR Convergence 2024
Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)
Jonathan Li¹, Paulina Horvei², Franziksa Rosser³, Kirsten Rose-Felker⁴, Vibha Sood⁵, Adam Olson⁶, Vickie Vandergrift⁷, Nicole Hogue², Lauren Farver⁸, Devin Mcguire⁹, Haley Havrilla⁷, Jessie Alexander¹⁰, Shawna McIntyre², Paul Szabolcs² and Kathryn Torok¹¹, ¹Division of Rheumatology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²Division of Blood and Marrow Transplantation and Cellular Therapies, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ³Division of Pulmonology Medicine, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁴Division of Cardiology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ⁵Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ⁶Department of Radiation Oncology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ⁷Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ⁸Department of Physical Therapy, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ⁹Pediatric Behavioral Health, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ¹⁰Pediatric Bone Marrow Transplant and Cellular Therapies, Stanford Children's Hospital, Palo Alto, CA, USA, Pittsburgh, ¹¹Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a systemic autoimmune disease characterized by vasculopathy and multiorgan fibrosis leading to significant morbidity and early mortality. Autologous stem…
Abstract Number: L06 • ACR Convergence 2023
Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)
Kathryn Torok¹, Paulina Horvei¹, Franziska Rosser¹, Kirsten Rose-felker², Vibha Sood², Adam Olsen², Nicole Hogue², Vickie Vandergrift², Lauren Farver², Devin Mcguire², Jonathan Li³, Haley Havrilla², Jessie Alexander⁴, Shawna McIntyre² and Paul Szabolcs¹, ¹University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Stanford Children's Hospital, Palo Alto, CA
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
Abstract Number: 0614 • ACR Convergence 2023
Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis
Liza Morales¹, Robert Spiera², Jessica Gordon¹, Deanna Jannat-Khah¹ and Kimberly Lakin¹, ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY
Background/Purpose: Few studies have investigated the prevalence and risk factors of sexual dysfunction among individuals with systemic sclerosis (SSc). The purpose of this study is…
Abstract Number: 1523 • ACR Convergence 2023
The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis
Muruganandam Maheswari, Eyerusalem Akpan, Matthew Mcelwee, Meredith Keller, Angie Ariza - Hutchinson, Rosemina Patel, Wilmer Sibbitt, Frank O'Sullivan, Sharon nunez, N. Suzanne Emil and Roderick Fields, University of New Mexico, Albuquerque, NM
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but a life-threatening complication of systemic sclerosis (SSc), affecting 2-15% of patients with SSc. SRC has been…
Abstract Number: 0628 • ACR Convergence 2023
Interstitial Lung Disease in Very Early Systemic Sclerosis
Sinziana Muraru¹, Carina Mihai¹, Anna-Maria Hoffmann-Vold², Cosimo Bruni¹, Muriel Elhai³, Mike Becker⁴, Suzana Jordan¹, Alexandru Garaiman¹, Oliver Distler¹ and Rucsandra Dobrota¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects around 50% of patients with systemic sclerosis (SSc) and is the main cause of mortality. Preliminary data from small…
Abstract Number: 1526 • ACR Convergence 2023
Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study
Lisa Kaly¹, mark Volevich¹, shiri keret², Abid Awisat³, Aniela Shouval¹, Itzhak Rosner⁴, Michel Rozenbaum¹, Nina Boulman¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion, Atlit, Israel, ³Bney-Zion Medical Center, Baqa Elgharbiya, Israel, ⁴Bnai Zion Medical Center/Technion, Haifa, Israel
Background/Purpose: B cell depleting therapy (rituximab) and Autologous Hematopoietic Stem Cell transplantation (AHSCT) result in impaired ability to mount a humoral immune response. Evusheld (tixagevimab…
Abstract Number: 0630 • ACR Convergence 2023
Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry
Marissa Savoie¹, Monica Harding², Jessica Alvey², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Laura Hummers¹⁰, Dinesh Khanna¹¹, Kimberly Lakin⁸, Dorota Lebiedz-Odrobina¹², Yiming Luo¹³, Ashima Makol¹⁴, Jerry Molitor¹⁵, Duncan Moore¹⁶, Carrie Richardson¹⁷, Nora Sandorfi¹⁸, Ami Shah¹⁹, Ankoor Shah²⁰, Brian Skaug²¹, Virginia Steen²², Elizabeth Volkmann²³ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Utah, Salt Lake City, UT, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹University of Michigan, Ann Arbor, MI, ¹²University of Utah, Cottonwood Heights, UT, ¹³Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁴Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶Northwestern University, Department of Rheumatology, Chicago, IL, ¹⁷Northwestern University, Chicago, IL, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²⁰Duke University, Durham, NC, ²¹Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²²Georgetown University School of Medicine, Washington, DC, ²³University of California Los Angeles, Los Angeles, CA
Background/Purpose: Digital ischemic ulcers (DIU) develop in 36-44% of patients with systemic sclerosis (SSc).1,2Prior international observational studies have evaluated characteristics of digital pitting and ulcers…
Abstract Number: 1528 • ACR Convergence 2023
Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients
Francesco Bonomi¹, Arianna Damiani¹, Carmela Coccia¹, Juela Levani¹, elisa Fiorentini², silvia peretti¹, Gemma Lepri¹, martina orlandi¹, francesca bartoli¹, marco Matucci Cerinic³, silvia bellando randone¹ and serena guiducci¹, ¹Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, ²Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, ³Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy
Background/Purpose: Treatment of systemic sclerosis (SSc) is challenging, and in the last 2 decades there has been an increasing interest for immunoglobulin (Igs) treatment as…
Abstract Number: 0635 • ACR Convergence 2023
Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center
Jessica Nguyen¹, Andrea Ramirez², Maria Pereira², Eyal Muscal³, Manuel Silva-Carmona² and Marietta De Guzman², ¹Baylor College of Medicine, Manvel, TX, ²Baylor College of Medicine, Houston, TX, ³Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare autoimmune multisystemic condition with immune, fibrotic, and vascular manifestations. Although progress has been made in recognizing this…
Abstract Number: 1663 • ACR Convergence 2023
Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells
Kimberly Lakin¹, Robert Spiera², Yaxia Zhang¹, David Oliver¹, Aliza Bloostein¹, Hiranmayi Ravichandran³, Niroshana Anandasabapathy³, Franck Barrat¹, Jessica Gordon¹ and Dana Orange⁴, ¹Hospital for Special Surgery, New York, NY, ²Hosptial for Special Surgery, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴The Rockefeller University, New York, NY
Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…

« Previous Page
1
…
5
6
7
8
9
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].